Patients are being overtreated with cancer drugs, as evidence suggests lower doses are often just as effective with fewer side effects. A study estimated $31 billion could have been saved in 2024 alone through dose optimization, but financial incentives for drugmakers and hospitals block this research. The FDA’s “Project Optimus” promotes lower-dose studies, but the agency lacks legal power to force drugmakers to test reduced dosages post-approval. Fewer than half of cancer drugs approved since 2000 have proven to extend survival, while the median price has quadrupled to $25,000 per month. Patient advocates demand informed consent, arguing people deserve plain…

Newswire

Features

The Latest